Lessons learned from HIV-1 vaccine trials: new priorities and directions.

A vaccine against human immunodeficiency virus (HIV) seems to be on the horizon. Correlates of risk of infection for [corrected] the RV144 vaccine trial have been found. There is understanding of what makes HIV envelope-specific antibodies broadly neutralizing and new T cell vaccine approaches can o...

Description complète

Détails bibliographiques
Auteurs principaux: Mcmichael, A, Haynes, B
Format: Journal article
Langue:English
Publié: 2012
Description
Résumé:A vaccine against human immunodeficiency virus (HIV) seems to be on the horizon. Correlates of risk of infection for [corrected] the RV144 vaccine trial have been found. There is understanding of what makes HIV envelope-specific antibodies broadly neutralizing and new T cell vaccine approaches can overcome virus variability.